Overview

Recombinant Human Erythropoietin Improve Neurodevelopmental Outcomes in Extremely Preterm Infants

Status:
Enrolling by invitation

Trial end date:
2022-12-01

Target enrollment:

Participant gender:

Summary

In the ELGAN (Extremely Low Gestational Age Newborn) study, abnormal brain structure and function were associated with intermittent or sustained systemic inflammation (ISSI). Since EPO has anti-inflammatory properties in the kidney and in muscle as well as growth/trophic properties. Based on its potential for neuroprotection, the prospective randomized and masked study was designed to determine whether rhEPO （500u/kg) was also effective in improving developmental outcomes for extremely low gestational age newborns.

Phase:

N/A

Details

Lead Sponsor:

Huiqing Sun

Collaborators:

Göteborg University
Zhengzhou University

Treatments:

Epoetin Alfa